Toxic protein-stopping Alzheimer's drug tested successfully
A drug that 'switches off' production of toxic amyloid proteins that lead to brain plaques, a characteristic of Alzheimer's patients, has been tested successfully by US pharmaceutical major Merck. The trial was primarily aimed to test safety, but after dosing early-stage Alzheimer's patients for seven days, it also reported reduction in levels of two compounds known to build abnormal proteins.